LifeTank a Physician Assistant Co.

Phone:

(951) 593-2747

Address:

1044 Cherry Valley Blvd. Ste. 430. Calimesa, CA 92320

The legal status of peptides

This is the part that changes fastest — and the part most misunderstood. "Legal to compound" is not the same as "FDA-approved," and neither one means "proven safe."

IMPORTANT INFO
This is a fast-moving area; always confirm the current position with the FDA directly.

Four buckets worth keeping straight

FDA-approved drug
Completed multi-phase human clinical trials for a specific use and carries an approved label. Example peptides: semaglutide, tirzepatide, tesamorelin, bremelanotide (PT-141), and — for a rare disease — afamelanotide (Melanotan I). This is the highest bar and the only bucket that means "studied in humans and authorised."
Compounded by a licensed pharmacy
A licensed pharmacy can prepare a medication for an individual patient under a valid prescription. This is a real, regulated practice — but a compounded product is not an FDA-approved drug, and the FDA does not verify each batch the way it does for approved products.[8] Whether a given peptide may be compounded depends on FDA "bulk substance" lists (below).
Investigational
Still in clinical trials, not approved for sale for human use. Example: retatrutide. Selling it for human consumption is not lawful, regardless of how it's labelled.
"Research Use Only" / grey market
Sold as a laboratory chemical "not for human consumption." This label is a legal workaround, not a safety claim — see Safety & the grey market.

The compounding lists: Category 1 vs. Category 2

For a peptide to be compounded from bulk powder under Section 503A, the FDA sorts candidate substances into categories while it reviews them:

  • Category 1 — eligible to be compounded by licensed pharmacies (with a prescription) under FDA's interim enforcement discretion while review continues.
  • Category 2 — identified as raising significant safety concerns or lacking data; may not be compounded.

In 2023, the FDA placed roughly 19 peptides into Category 2, which effectively shut licensed compounding pharmacies out of preparing them — pushing demand toward the grey market.

The 2026 reclassification — and why it proves the point

This is the development to understand right now — and the details matter, because the headlines and the paperwork don't quite line up:

  1. Feb 27, 2026: HHS Secretary Robert F. Kennedy Jr. announced that about 14 of the 19 restricted peptides would move from Category 2 back toward Category 1.[3] That was a statement of intent — not, by itself, a change in the rules.
  2. April 15–16, 2026: the FDA actually acted, but on 12 specific peptide bulk substances: it announced their removal from Category 2 within seven days (because the original nominations were withdrawn) and published a Federal Register notice scheduling advisory-committee review.[1, 2, 4] The "14" and the "12" are both real — one was the announcement, the other was the action.
  3. The crucial catch: removal from Category 2 does not place a substance in Category 1 or on the bulks list. These 12 peptides entered a regulatory gray area — no longer formally "do-not-compound," but not yet authorised either.[4, 5]
  4. July 23–24, 2026: the FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review seven of them for the 503A bulks list — on July 23, BPC-157, KPV, TB-500, and MOTS-c; on July 24, Emideltide (DSIP), Semax, and Epitalon.[1, 2, 6]
  5. Before the end of February 2027: a second PCAC meeting is set to review the remaining five — GHK-Cu, Melanotan II, LL-37 (cathelicidin), Dihexa, and PEG-MGF.[6] (Note that Melanotan II, often assumed to be staying banned, is in fact in this review batch — though its safety record makes the outcome far from certain.)
  6. Still outside this process: peptides like CJC-1295 were not advanced; FDA documentation has cited adverse nonclinical findings for it, including DNA damage in pituitary cells.[7]

Here is the crucial nuance. Even after this reclassification:

  • Removal from Category 2 is not FDA approval. None of these peptides has completed the clinical-trial process required to be an approved drug.[4, 6]
  • PCAC is only advisory; formal FDA rulemaking must still happen before pharmacies may actually compound a substance off the bulks list.[5, 6]
  • A procedural removal from Category 2 is explicitly not a green light to compound, and does not bring a substance within FDA's Category 1 enforcement-discretion policy.[5]
  • Selling these as "research chemicals" for human consumption remains unlawful, reclassification or not.[7]

So the 2026 story is genuinely hopeful — it points toward regulated, prescription, quality-controlled access through licensed pharmacies and away from anonymous vials. But it is the clearest possible illustration of the site's core message: a change in legal status is a change in paperwork, not a guarantee about your safety.

MENU